# US 2004/0063108 A1 · Methods of diagnosis of colorectal cancer, compositions and methods of screening for modulators of colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0063108 A1
- Document ID: US20040063108A1
- Status: Published application
- Kind: A1
- Application number: 10/318,578
- Filed: 2002-12-12
- Published: 2004-04-01
- Earliest claimed: 2001-12-13
- Assignees: Eos Biotechnology, Inc.; Case Western Reserve University
- Inventors: David H. Mack; Sanford David Markowitz; Thomas Ried
- Web page: https://patentgrep.com/patent/US20040063108A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Described herein are methods and compositions that can be used for diagnosis and treatment of colorectal cancer. Also described herein are methods that can be used to identify modulators of colorectal cancer.

## Claims

### Claim 1

A method of detecting a colorectal cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Table 1, 1A or 1B.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biological sample is a tissue sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biological sample comprises isolated nucleic acids.

### Claim 5 (depends on 4)

The method of claim 4, wherein the nucleic acids are mRNA.

### Claim 6 (depends on 4)

The method of claim 4, further comprising the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polynucleotide comprises a sequence as shown in Table 1, 1A or 1B.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polynucleotide is labeled.

### Claim 9 (depends on 8)

The method of claim 8, wherein the label is a fluorescent label.

### Claim 10 (depends on 1)

The method of claim 1, wherein the polynucleotide is immobilized on a solid surface.

### Claim 11 (depends on 1)

The method of claim 1, wherein the patient is undergoing a therapeutic regimen to treat colorectal cancer.

### Claim 12 (depends on 1)

The method of claim 1, wherein the patient is suspected of having colorectal cancer.

### Claim 13

A method of monitoring the efficacy of a therapeutic treatment of colorectal cancer, the method comprising the steps of:
(i) providing a biological sample from a patient undergoing the therapeutic treatment; and
(ii) determining the level of a colorectal cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B, thereby monitoring the efficacy of the therapy.

### Claim 14 (depends on 13)

The method of claim 13, further comprising the step of: (iii) comparing the level of the colorectal cancer-associated transcript to a level of the colorectal cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

### Claim 15 (depends on 13)

The method of claim 13, wherein the patient is a human.

### Claim 16

A method of monitoring the efficacy of a therapeutic treatment of colorectal cancer, the method comprising the steps of:
(i) providing a biological sample from a patient undergoing the therapeutic treatment; and
(ii) determining the level of a colorectal cancer-associated antibody in the biological sample by contacting the biological sample with a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B, wherein the polypeptide specifically binds to the colorectal cancer-associated antibody, thereby monitoring the efficacy of the therapy.

### Claim 17 (depends on 16)

The method of claim 16, further comprising the step of: (iii) comparing the level of the colorectal cancer-associated antibody to a level of the colorectal cancer-associated antibody in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

### Claim 18 (depends on 16)

The method of claim 16, wherein the patient is a human.

### Claim 19

A method of monitoring the efficacy of a therapeutic treatment of colorectal cancer, the method comprising the steps of:
(i) providing a biological sample from a patient undergoing the therapeutic treatment; and
(ii) determining the level of a colorectal cancer-associated polypeptide in the biological sample by contacting the biological sample with an antibody, wherein the antibody specifically binds to a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B, thereby monitoring the efficacy of the therapy.

### Claim 20 (depends on 19)

The method of claim 19, further comprising the step of: (iii) comparing the level of the colorectal cancer-associated polypeptide to a level of the colorectal cancer-associated polypeptide in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

### Claim 21 (depends on 19)

The method of claim 19, wherein the patient is a human.

### Claim 22

An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Table 1, 1A or 1B.

### Claim 23 (depends on 22)

The nucleic acid molecule of claim 22, which is labeled.

### Claim 24 (depends on 23)

The nucleic acid of claim 23, wherein the label is a fluorescent label

### Claim 25 (depends on 22)

An expression vector comprising the nucleic acid of claim 22.

### Claim 26 (depends on 25)

A host cell comprising the expression vector of claim 25.

### Claim 27

An isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Table 1, 1A or 1B.

### Claim 28 (depends on 27)

An antibody that specifically binds a polypeptide of claim 27.

### Claim 29 (depends on 28)

The antibody of claim 28, further conjugated to an effector component.

### Claim 30 (depends on 29)

The antibody of claim 29, wherein the effector component is a fluorescent label.

### Claim 31 (depends on 29)

The antibody of claim 29, wherein the effector component is a radioisotope or a cytotoxic chemical.

### Claim 32 (depends on 29)

The antibody of claim 29, which is an antibody fragment.

### Claim 33 (depends on 29)

The antibody of claim 29, which is a humanized antibody

### Claim 34 (depends on 28)

A method of detecting a colorectal cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody of claim 28.

### Claim 35 (depends on 34)

The method of claim 34, wherein the antibody is further conjugated to an effector component.

### Claim 36 (depends on 35)

The method of claim 35, wherein the effector component is a fluorescent label.

### Claim 37

A method of detecting antibodies specific to colorectal cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprises a sequence from Table 1, 1A or 1B.

### Claim 38

A method for identifying a compound that modulates a colorectal cancer-associated polypeptide, the method comprising the steps of:
(i) contacting the compound with a colorectal cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B; and
(ii) determining the functional effect of the compound upon the polypeptide.

### Claim 39 (depends on 38)

The method of claim 38, wherein the functional effect is a physical effect.

### Claim 40 (depends on 38)

The method of claim 38, wherein the functional effect is a chemical effect.

### Claim 41 (depends on 38)

The method of claim 38, wherein the polypeptide is expressed in a eukaryotic host cell or cell membrane.

### Claim 42 (depends on 38)

The method of claim 38, wherein the functional effect is determined by measuring ligand binding to the polypeptide.

### Claim 43 (depends on 38)

The method of claim 38, wherein the polypeptide is recombinant.

### Claim 44 (depends on 38)

A method of inhibiting proliferation of a colorectal cancer-associated cell to treat colorectal cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified using the method of claim 38.

### Claim 45 (depends on 44)

The method of claim 44, wherein the compound is an antibody.

### Claim 46 (depends on 45)

The method of claim 45, wherein the patient is a human.

### Claim 47

A drug screening assay comprising the steps of
(i) administering a test compound to a mammal having colorectal cancer or a cell isolated therefrom;
(ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of colorectal cancer.

### Claim 48 (depends on 47)

The assay of claim 47, wherein the control is a mammal with colorectal cancer or a cell therefrom that has not been treated with the test compound.

### Claim 49 (depends on 47)

The assay of claim 47, wherein the control is a normal cell or mammal.

### Claim 50 (depends on 47)

A method for treating a mammal having colorectal cancer comprising administering a compound identified by the assay of claim 47.

### Claim 51 (depends on 47)

A pharmaceutical composition for treating a mammal having colorectal cancer, the composition comprising a compound identified by the assay of claim 47 and a physiologically acceptable excipient.
